• Wondering whether Silicon Laboratories at around US$217.64 is offering value or stretching expectations, especially after its strong share price performance, is a natural place to start.
• The stock has been relatively steady over the past week, while the 30 day return is 3.6%, year to date the share price return is 65.0% and the 1 year return sits at 95.9%.
• Recent coverage has focused on Silicon Laboratories in the context of the broader semiconductor sector, including how specialist chip suppliers are positioned as connectivity and embedded solutions remain in focus. Commentators have also been highlighting how investor attention on companies exposed to connected devices and industrial applications can influence sentiment around stocks like this.
• Despite those strong returns, Silicon Laboratories currently has a valuation score of 1 out of 6. The next sections will walk through traditional valuation checks and then finish with a broader way of thinking about what the stock might be worth.

Silicon Laboratories scores just 1/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: Silicon Laboratories Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a stock might be worth today by projecting the cash the company could generate in the future and then discounting those cash flows back to a present value.

For Silicon Laboratories, the model used is a 2 Stage Free Cash Flow to Equity approach, working off last twelve months free cash flow of about $26.9 million. Analysts provide explicit forecasts for the early years, and cash flows further out are extrapolated based on those inputs by Simply Wall St. The projections run out to 2035, with free cash flow in that year estimated at $238.3 million, discounted back to today at $84.7 million.

Combining all projected and discounted cash flows results in an estimated intrinsic value of about $64.83 per share. Compared with the recent share price around $217.64, the model indicates Silicon Laboratories is trading well above this estimate of fair value, with the DCF output suggesting the stock is 235.7% higher than the model’s valuation.

Result: OVERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Silicon Laboratories may be overvalued by 235.7%. Discover 51 high quality undervalued stocks or create your own screener to find better value opportunities.

Approach 2: Silicon Laboratories Price vs Sales

For companies where earnings can be less reliable or negative, the P/S ratio is often a practical way to think about value because it focuses on revenue, which tends to be more stable than earnings.

What counts as a reasonable P/S ratio usually reflects how the market views a company’s growth outlook and risk profile. Higher expected growth or perceived lower risk can be associated with higher P/S multiples, while slower growth or higher risk tends to justify lower ones.

Silicon Laboratories currently trades on a P/S ratio of 8.75x. That sits slightly above the Semiconductor industry average of 8.65x and above the peer group average of 7.60x. Simply Wall St also calculates a proprietary “Fair Ratio” for Silicon Laboratories of 9.66x, which estimates the P/S multiple that might be expected given factors such as its growth profile, profit margins, size, industry and risk characteristics.

This Fair Ratio can be more informative than a simple comparison with the industry or peers, because it tries to align the multiple with company specific fundamentals rather than broad group averages. Since the Fair Ratio of 9.66x is higher than the current P/S of 8.75x, this framework indicates that Silicon Laboratories appears undervalued on this metric.

Result: UNDERVALUED

P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies.

Upgrade Your Decision Making: Choose your Silicon Laboratories Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St let you turn your view of Silicon Laboratories into a clear story that links its business, a financial forecast and a fair value, then compares that to today’s price in real time as new news or earnings arrive. You can see, for example, how a more optimistic Narrative that lines up with a US$231.00 fair value and assumes higher margins and a future P/E of about 47.8x differs from a more cautious Narrative closer to US$135.00 that assumes lower future margins and a higher required P/E of about 86.9x. All of this is available within an accessible tool inside the Community page that millions of investors already use to decide whether the current price or their own Fair Value estimate has moved enough for them to consider buying or selling.

For Silicon Laboratories however we will make it really easy for you with previews of two leading Silicon Laboratories Narratives:

These sit on opposite sides of the debate, so you can quickly see what needs to be true for either the more optimistic or the more cautious view to make sense at around US$217.64.

Fair value in this Narrative: US$222.86

Implied pricing vs this fair value: around 2.3% below the Narrative fair value

Revenue growth assumption: 16.40% a year

• Assumes Silicon Laboratories grows revenue to US$1.2b and lifts profit margins toward the broader US Semiconductor industry over time.
• Builds in a future P/E of about 47.8x on earnings of roughly US$217.0m by 2029, backed by expectations for higher margin IoT centric products and tighter cost control.
• Views the current price as broadly aligned with analyst targets, provided the company delivers on IoT expansion, security led differentiation and margin improvement while managing competitive and regulatory risks.

Fair value in this Narrative: US$135.00

Implied pricing vs this fair value: around 61.2% above the Narrative fair value

Revenue growth assumption: 16.27% a year

• Assumes similar top line growth but a much lower profit margin of about 5.9% by 2029, with earnings around US$72.3m and heavier reliance on a high P/E multiple of roughly 86.9x to justify the share price.
• Flags the risk that industrial IoT, smart meters, wireless asset tracking and medical ramps do not scale as expected, which could pressure mix, gross margin and operating leverage.
• Frames the current price as rich relative to this fair value, with outcomes highly sensitive to adoption of new platforms, the success of tools like Studio 6 and Simplicity AI SDK, and how competitive and regulatory trends play out.

Do you think there's more to the story for Silicon Laboratories? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.